Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jagadeesh Aluri
Observed names:
Aluri, Jagadeesh,
J ALURI,
J. Aluri,
J.B. Aluri
Institution:
Eisai (United States)
Observed institutions:
GlaxoSmithKline (United States),
Dana-Farber Cancer Institute,
EA Pharma (Japan),
Eisai (United Kingdom),
Eisai (United States),
Eisai (Japan),
The University of Texas at Austin
show all 7
OpenAlex ID:
A5113714866
Effect of Rifampicin on the Pharmacokinetics of Lenvatinib in Healthy Adults
2014
·
Robert C. Shumaker
, Jagadeesh Aluri
, et al.
·
Clinical Drug Investigation
·
75
PDF
Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single‐Dose and Multiple‐Ascending‐Dose Phase 1 Studies in Healthy Adults
2020
·
Ishani Landry
, Kenya Nakai
, et al.
·
Clinical Pharmacology in Drug Development
·
70
PDF
Influence of hepatic impairment on lenvatinib pharmacokinetics following single‐dose oral administration
2014
·
Robert Shumaker
, Jagadeesh Aluri
, et al.
·
The Journal of Clinical Pharmacology
·
56
PDF
O1‐06‐05: First‐in‐human study of E2609, a novel BACE1 inhibitor, demonstrates prolonged reductions in plasma beta‐amyloid levels after single dosing
2012
·
Robert Lai
, Bruce Albala
, et al.
·
Alzheimer s & Dementia
·
56
Pharmacokinetics, Pharmacodynamics, Pharmacogenomics, Safety, and Tolerability of Avatrombopag in Healthy Japanese and White Subjects
2017
·
Maiko Nomoto
, Gina Pastino
, et al.
·
Clinical Pharmacology in Drug Development
·
53
Effects of ketoconazole on the pharmacokinetics of lenvatinib (E7080) in healthy participants
2014
·
Robert Shumaker
, Jagadeesh Aluri
, et al.
·
Clinical Pharmacology in Drug Development
·
52
PDF
Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers
2014
·
Robert Shumaker
, Jagadeesh Aluri
, et al.
·
International Journal of Clinical Pharmacology and Therapeutics
·
44
Effect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteers
2014
·
Robert C. Shumaker
, Meijian Zhou
, et al.
·
Cancer Chemotherapy and Pharmacology
·
38
Concentration–Response Modeling of ECG Data From Early‐Phase Clinical Studies as an Alternative Clinical and Regulatory Approach to Assessing QT Risk — Experience From the Development Program of Lemborexant
2016
·
Patricia J. Murphy
, Sanae Yasuda
, et al.
·
The Journal of Clinical Pharmacology
·
33
Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users
2022
·
Ishani Landry
, Nancy Hall
, et al.
·
Journal of Clinical Psychopharmacology
·
28
Determination of guaifenesin in human plasma by liquid chromatography in the presence of pseudoephedrine
1993
·
J.B. Aluri
, S. Stavchansky
·
Journal of Pharmaceutical and Biomedical Analysis
·
28
Pharmacokinetic/pharmacodynamic drug–drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs
2018
·
Maiko Nomoto
, Cynthia A. Zamora
, et al.
·
British Journal of Clinical Pharmacology
·
27
Disposition and Metabolism of [14C]Lemborexant in Healthy Human Subjects and Characterization of Its Circulating Metabolites
2020
·
Takashi Ueno
, Tomomi Ishida
, et al.
·
Drug Metabolism and Disposition
·
26
PDF
Pharmacokinetics and Pharmacodynamics of Argatroban in Combination With a Platelet Glycoprotein IIB/IIIA Receptor Antagonist in Patients Undergoing Percutaneous Coronary Intervention
2004
·
Donna S. Cox
, Neal S. Kleiman
, et al.
·
The Journal of Clinical Pharmacology
·
26
Evaluation of the CYP3A and CYP2B6 Drug‐Drug Interaction Potential of Lemborexant
2021
·
Ishani Landry
, Jagadeesh Aluri
, et al.
·
Clinical Pharmacology in Drug Development
·
22
PDF
Population Pharmacokinetics and Exposure‐Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder
2020
·
Bojan Lalovic
, Oneeb Majid
, et al.
·
The Journal of Clinical Pharmacology
·
22
PDF
An Anti-tau Therapeutic Antibody Etalanetug (E2814)
2025
·
Sumit Rawal
, Kristin R. Wildsmith
, et al.
·
Alzheimer Disease & Associated Disorders
·
21
First‐in‐Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742, a Dual Antagonist of Toll‐like Receptors 7 and 8, in Healthy Volunteers
2022
·
Naoto Yamakawa
, Fumitoshi Tago
, et al.
·
Clinical Pharmacology in Drug Development
·
21
S4‐04‐01: CSF amyloid lowering in human volunteers after 14 days’ oral administration of the novel BACE1 inhibitor E2609
2012
·
Bruce Albala
, June M. Kaplow
, et al.
·
Alzheimer s & Dementia
·
16
Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: A randomized, placebo-controlled crossover study
2022
·
Ishani Landry
, Nancy Hall
, et al.
·
Journal of Psychopharmacology
·
12
Effect of gastric acid‐reducing agents on the pharmacokinetics and efficacy of lemborexant
2020
·
Ishani Landry
, Jagadeesh Aluri
, et al.
·
Pharmacology Research & Perspectives
·
12
PDF
E2814: an anti‐tau therapy engages its CNS target and affects the downstream tangle‐specific biomarker MTBR‐tau243 in Dominantly Inherited Alzheimer’s Disease
2023
·
Jin Zhou
, Sumit Rawal
, et al.
·
Alzheimer s & Dementia
·
11
PDF
Phase 1 Single Ascending and Multiple Ascending Dose Studies of Phosphodiesterase-9 Inhibitor E2027
2022
·
Ishani S. Landry
, Jagadeesh Aluri
, et al.
·
Alzheimer Disease & Associated Disorders
·
10
Intravenous Perampanel as an Interchangeable Alternative to Oral Perampanel: A Randomized, Crossover, Phase I Pharmacokinetic and Safety Study
2022
·
Ziad Hussein
, Oneeb Majid
, et al.
·
Clinical Pharmacology in Drug Development
·
10
Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant
2021
·
Ishani Landry
, Jagadeesh Aluri
, et al.
·
Pharmacology Research & Perspectives
·
10
Show more works
View as search
Works count:
65
Citation count:
878
H-index:
18
I10-index:
25
Year
Topic
Type
